Artiva Biotherapeutics Future Growth
Future criteria checks 2/6
Artiva Biotherapeutics's earnings are forecast to decline at 20.6% per annum while its annual revenue is expected to grow at 63.1% per year. EPS is expected to grow by 29.5% per annum.
Key information
-20.6%
Earnings growth rate
29.5%
EPS growth rate
| Biotechs earnings growth | 28.4% |
| Revenue growth rate | 63.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 21 Nov 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -91 | -63 | -71 | 4 |
| 12/31/2025 | N/A | -76 | -54 | -58 | 5 |
| 12/31/2024 | 0 | -66 | -59 | -48 | 5 |
| 9/30/2024 | 3 | -61 | -52 | -51 | N/A |
| 6/30/2024 | 29 | -33 | -51 | -50 | N/A |
| 3/31/2024 | 33 | -26 | -50 | -48 | N/A |
| 12/31/2023 | 33 | -29 | -51 | -47 | N/A |
| 3/31/2023 | 5 | -63 | -63 | -55 | N/A |
| 12/31/2022 | 5 | -59 | -57 | -51 | N/A |
| 3/31/2022 | 3 | -41 | -36 | -33 | N/A |
| 12/31/2021 | 2 | -72 | -17 | -15 | N/A |
| 9/30/2021 | 1 | -66 | -13 | -12 | N/A |
| 12/31/2020 | N/A | -18 | -14 | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARTV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ARTV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ARTV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ARTV's revenue (63.1% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: ARTV's revenue (63.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ARTV's Return on Equity is forecast to be high in 3 years time